Acute Hip Fracture Study in Patients 65 Years or Greater

Completed · Phase 2 · Has a placebo group

Conditions studied: Hip Fractures

In brief

This is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to investigate the safety, tolerability, and efficacy of VK5211 after 12 weeks of treatment. Males and females ≥65 years old who are ambulatory and recovering from a hip fracture will be eligible for participation 3-7 weeks post-injury.

Key facts

Study ID
NCT02578095
Run by
Viking Therapeutics, Inc.
People needed
108
Starts
2015-10-30
Expected to finish
2017-12-17
Last updated by the study team
2025-12-29

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.